Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: J Cyst Fibros. 2020 Jul 12;19(6):942–948. doi: 10.1016/j.jcf.2020.07.009

Table 1:

Subject Demographics

Active (6% NaCl) (n=14) Placebo (0.12% NaCl) (n=9) All subjects (n = 23)
Female, % 8 (57%) 4 (44%) 12 (52%)
Age, years (SD) 11.9 (3.3) 9.8 (3.6) 11.1 (3.5)
Post-BD FVC, % predicted (SD) 101.4 (12.3) 100.0 (10.9) 100.8 (11.5)
Post-BD FEV1, % predicted (SD) 97.0 (12.6) 93.2 (13.4) 95.5 (12.8)
Post-BD FEF25–75, % predicted (SD) 91.1 (24.9) 86.2 (37.8) 89.7 (27.9)
Inhaled antibiotics (%) 2 (14%) 1 (11%) 3 (13%)
Chronic HS (%) 1 (7%) 3 (33%) 4 (17%)
Dornase Alfa (%) 3 (36%) 4 (44%) 9 (39%)
Pancreatic Sufficient (%) 0 (0%) 1 (11%) 1 (4%)

Abbreviations: SD – Standard Deviation, BD – bronchodilator, FVC – forced vital capacity, FEV1 – Forced Expiratory Volume in 1 second, FEF25–75 - Forced expiratory flow 25–75%. No subjects used CFTR modulators during this study.